Pharmaleaders TV
You are here:  / Breaking News / Business / Indian News / News Makers / Trending / World news / Dr. Datsons Labs set to appoint a professional CEO & MD to drive the new Management & Untapped Market, Founder Promoter Dr. Kannan Vishwanath to step down

Dr. Datsons Labs set to appoint a professional CEO & MD to drive the new Management & Untapped Market, Founder Promoter Dr. Kannan Vishwanath to step down

Mahad-Fctory

Datsons Lab Ltd, formerly known as  Dr Datsons Lifecare Ltd, BSE code (533412) is all set to restructure the composition of the Board Management on Feb 14 2015 when the quarter results will be announced. Sources close to Pharmaleaders reveal that the troubled drug maker which is one of the largest contract manufacturers of codeine based cough syrups in India having state-of-the-art; WHO GMP approved facilities for manufacturing bulk drugs at Mahad and finished dosage forms at Pirungut near Pune will be forming a new Board Management with an appointment of a professional CEO & MD to drive the operations of the company. Founder Promoter Dr. Kannan Vishwanath will be stepping down from the day to day operations paving the way for a new management to steer the company’s business under a new Board MD & CEO.

The move is seen to create a new business environment to bring its lost glory of the world’s largest third-largest quinine salts manufacturer in the world and among the-largest controlled substances quota in India. It is also having a dominant position in Anti Cancer and Anti Malarial drugs worldwide. In the peak of its business, it was once the darling of the stock market which rose to an enviable price of 860 in last year & was witness to many landmark deals including the acquisition of hyderbad based bulk drug company Apex Laboratories for Rs 250 crore.

Experts see this development as a positive sign of revamping the business under a new Management headed by a professional CEO & MD. The Company is expected to close all the deals that it striked in past to give a fresh lease of life by a new management with a professional CEO & MD at the helm. What role the promoters will play is still not clear but the move will certainly see a major jump from its earlier functioning. The Company in the past had successfully raised about Rs. 117 crore from its IPO. The positive news for the new CEO & MD is the following that will have the advantages.

It is the world’s third-largest manufacturer of quinine salts and the second-largest in India. Only nine companies globally manufacture quinine salts. ADr Datsons is only the second company to receive WHO prequalification for its anti-malarial APIs and formulations.

  • It is one of the most cost-effective quinine manufacturers
  • One of the largest codeine quota holders in the pharmaceutical sector
  • The only manufacturer of multi- flavored Lozenge medical products in India
  • The only company in India to be classified as ethical prescription dosages for diverse therapeutic segments. It is positioned as a global Centre of Excellence in the area of Lozenge manufacture
  • The company pioneered the recognition that lozenges represent a stable platform for the delivery of pharmaceutical and nutraceutical ingredients
  • Dr Datsons’s Nicco Nil lozenge is a first-of-its-kind remedy in the world for smoking de-addition; its Relacs is a first-time lozenge against insomnia in India, and Arecta Plus, a lozenge variant for Viagra, is a first for India.
  • The company has an expertise in opportunity spotting and innovation. The company’s success has been built on a business model that integrates Research, Innovation and Knowledge. The company has invested in building proprietary Knowledge through research and acquisitions.
  • Anajaneyas Lifecare’s competence has been validated through patents granted by international and Indian authorities.
  • Highlights 2011-2012 for Active Pharmaceutical Ingredents. Production of Quinine Sulphate increased 30% in 2011-2012
  • Sales of Quinine Sulphate grew 45%
  • Exports increased 250% from Rs 10 Crore to Rs 31 crore
  • Added 35 international and 50 domestic clients
  • Completed trials for Bromexine(expectorant)a new API that will be launched in 2012-1023
  • Highlights 2011-2012 for Finished Dosage Forms. Launched ‘Rancorex’ an in-house codine based cough syrup brand for the first time in its history
  • received the Kenya PPB GMP approval from all facilities namely lozenges,liquids and iontments
  • Received registration for ‘Arecta Plus'(a lozenge variant of Viagra tablets)from Sierrs Leone and Libya; received the first export order for this product to be executed in 2012-2013

The change in the Board Management & a new business approach can be expected from the 14th Feb Quarter results where the company will announce the developments.

PHARMALEADERS

Pharmaleaders is India’s first opinion based & research driven bi-monthly magazine & has a decade of relentless reporting in Pharma Journalism in an unbiased, fearless & independent way. Over the last one decade, The Magazine has covered some of the biggest voices in the healthcare Industry. Available both in digital & printed format, Pharmaleaders has emerged out as a leading title in voicing the opinion of the healthcare industry.

LEAVE A REPLY

Your email address will not be published. Required fields are marked ( required )

September 2017
M T W T F S S
« Aug    
 123
45678910
11121314151617
18192021222324
252627282930  
Follow us
Contact us

Network 7 Meadia Group

Bangalore Ph: 080 0000 0000 Mail: editor@pharmaleader.tv